YourEra Review

YourEra: a rock-bottom entry price with a lot left unsaid

YourEra is a fully online telehealth service built around one very loud promise: get started on a compounded GLP-1 for $99 your first month. That headline rate covers compounded semaglutide or compounded tirzepatide, and it is among the lowest first-month figures anywhere in this category. The catch — and it's a real one — is that almost everything past that first month is left for you to find out after you've already started the intake. If you want a cheap, no-friction way to try a compounded GLP-1 and you're willing to ask pointed questions before you commit, YourEra is worth a look. If you want every cost and detail spelled out before you hand over a payment, this is not the most transparent option on the market.

How the $99 pricing actually works

The $99 figure is an entry rate for your first month, not a locked-in monthly price. YourEra does not publish what the ongoing maintenance dose costs once you move past that introductory month — and that's the single most important thing to understand here. A teaser price only matters if the steady-state price is reasonable, and right now you can't see it without going through the medical intake first. Before you let that first charge go through, ask plainly what the recurring monthly cost will be once the promo month ends.

There is one pricing detail in YourEra's favor: the site advertises a "Same Price at Every Dose" guarantee, meaning your cost shouldn't climb as your prescriber titrates you up to a higher dose. That's a genuinely patient-friendly structure — plenty of competitors charge more as your dose increases. YourEra also says it's FSA- and HSA-eligible across all plans, which can quietly shave the real cost if you have one of those accounts. For reference, the category median runs around $169 a month, so even a modestly priced maintenance tier here could land below average.

The medications and how they're dispensed

YourEra prescribes compounded semaglutide and compounded tirzepatide — the same active ingredients found in the brand-name GLP-1s, prepared by compounding pharmacies rather than the original manufacturers. To the company's credit, it states this plainly on its own site: these are not Ozempic, Wegovy, Mounjaro, or Zepbound. That kind of candor is unusual in a corner of the industry where a lot of marketing blurs the line, and it's the clearest signal that YourEra is being straight with you about what you're actually buying.

Everything runs remotely. YourEra describes its model as "100% online doctor visits and prescriptions," so there's no in-person clinic step — you complete an intake, a licensed prescriber reviews it, and the medication ships if you're cleared. The medications are made by what the company calls "state-licensed pharmacies that follow applicable state and federal regulations."

What's missing — and why it matters

Compounded GLP-1s are only as trustworthy as the pharmacy behind them, and this is where YourEra gets thin. It does not name its compounding pharmacy partners, list their accreditations, or disclose where they're located. "State-licensed pharmacies" is a regulatory baseline, not a quality credential. The gaps don't stop there:

• The ongoing maintenance-dose price isn't published — only the first-month entry rate is verified.
• The compounding pharmacy partners aren't named, so you can't independently check their accreditation or track record.
• Per-state availability isn't listed; there's no published map of where YourEra actually ships, so confirm your state is covered before paying.
• Any consultation fee, lab-work requirement, and ongoing-care details aren't spelled out up front.
• The legal entity name and state of incorporation aren't disclosed, which makes the company harder to vet.

Trust and safety: what we can and can't confirm

On the positive side, YourEra displays a LegitScript certification, which is a meaningful third-party check — LegitScript verifies that an online pharmacy or telehealth operation meets legal and safety standards, and it's not trivial to earn. We also found no FDA warning letters on file for YourEra. So the foundational safety signal is reasonable. Our verification confidence is medium rather than high, though, because the LegitScript seal isn't paired with a visible approval number on the home page, the legal entity isn't named, and the pharmacy chain is anonymous. You're trusting a certification badge more than a fully documented operation.

Who should choose YourEra — and who should skip it

Choose YourEra if your top priority is the cheapest possible way to start a compounded GLP-1, you value the flat "same price at every dose" structure, and you're comfortable asking for the ongoing price and shipping details directly before you commit. The honesty about compounded-vs-brand and the LegitScript certification make it a defensible budget pick.

Skip it if you want full transparency up front. Patients who need to know their long-term monthly cost, the name and accreditation of the pharmacy filling their prescription, and exactly what's included before paying will find better-documented options elsewhere. There's nothing alarming on file here — but there's a lot simply not disclosed, and for a medication you may take for a year or more, that opacity is a fair reason to pass.

Bottom line

YourEra leads with one of the lowest first-month prices in the GLP-1 telehealth space and backs it with a flat-dose pricing guarantee, LegitScript certification, and refreshingly honest labeling of its compounded medications. The weakness is everything it leaves unstated: the real ongoing cost, the pharmacy partners, state coverage, and the company's own legal identity. Treat the $99 first month as a low-risk trial, not a long-term commitment, and pin down the recurring price and shipping eligibility before you continue. For a deeper look at how we weigh price transparency against safety signals, see our scoring methodology.

Worth pricing against Sesame Care ($59/month) and bmiMD ($99/month) before you commit — both sit close to YourEra on cost and formulation.